Aim: It has been indicated that COVID-19 is related to many endocrinological abnormalities. The aim of this study is to demonstrate whether there is an impact of COVID-19 and COVID-19 vaccines on development of subacute thyroiditis (SAT).
Material and Method: This retrospective single-center study includes individuals with SAT who were diagnosed between March 2020 and August 2021. Patients were evaluated for a recent Covid-19 history and SARS-CoV-2 vaccination. SAT was diagnosed based on the clinical presentation and laboratory tests; including thyroid function tests, sedimentation rate, C-reactive protein, and thyroid ultrasound. SARS-CoV-2 PCR results of patients with past COVID-19 were obtained from the Ministry of Health electronic patient data system. Type, number, and dates of vaccine doses were recorded for each participant.
Results: A total of 31 patients were included in the study. Six patients (19.4%) were diagnosed with SAT following a COVID-19 vaccination schedule. Four patients with SAT had received two inactive (CoronaVac) + one dose of mRNA vaccines (Pfizer-BioNTech). The other 2 patients had received either two doses of inactive vaccine or two doses of mRNA vaccine. Five patients were diagnosed with SAT after the second dose of the vaccine. The median interval between last vaccination dose and diagnosis of SAT was 25.8 days. In one patient, SAT developed 28 days after the mRNA vaccine. Seven patients (22.6%) were diagnosed with SAT after COVID-19 disease. The median interval from the diagnosis of COVID-19 disease to SAT was 27.3 days. All cases of post-COVID-19 and post-vaccination SAT patients exhibited similar clinical presentation and findings to idiopathic SAT.
Conclusion: Covid-19 itself and Covid-19 vaccines might let a tendency to development of subacute thyroiditis. This study has to be supported by further studies.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Research Articles |
Authors | |
Early Pub Date | March 24, 2022 |
Publication Date | March 29, 2022 |
Published in Issue | Year 2022 Volume: 4 Issue: 2 |
TR DİZİN ULAKBİM and International Indexes (1b)
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS]
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/3449/file/4924/show
Journal Indexes and Platforms:
TR Dizin ULAKBİM, Google Scholar, Crossref, Worldcat (OCLC), DRJI, EuroPub, OpenAIRE, Turkiye Citation Index, Turk Medline, ROAD, ICI World of Journal's, Index Copernicus, ASOS Index, General Impact Factor, Scilit.The indexes of the journal's are;
The platforms of the journal's are;
The indexes/platforms of the journal are;
TR Dizin Ulakbim, Crossref (DOI), Google Scholar, EuroPub, Directory of Research Journal İndexing (DRJI), Worldcat (OCLC), OpenAIRE, ASOS Index, ROAD, Turkiye Citation Index, ICI World of Journal's, Index Copernicus, Turk Medline, General Impact Factor, Scilit
EBSCO, DOAJ, OAJI is under evaluation.
Journal articles are evaluated as "Double-Blind Peer Review"